The doctor explained everything about this medication and listened as well as answered my questions
Data suggest that semaglutide may lower the 10-year risk of developing type 2 diabetes by as much as 60% in people with overweight and weight-related complications or with obesity while on treatment
Patients: 1864 adult patients with inadequately controlled type 2 diabetes (7.0%-10.5%) receiving metformin alone or metformin with a sulfonylurea were randomized to semaglutide tablets 14 mg (n=465), 7 mg (n=466), 3 mg (n=466), or Januvia 100 mg (n=467), all once daily
Patients were assigned to either semaglutide 0.5 mg, dulaglutide 0.75 mg, semaglutide 1.0 mg or dulaglutide 1.5 mg
Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study
Data sources and search strategy To identify relevant literature, searches were conducted using the ClinicalTrials.gov database and PubMed